Management of 60‑79 % Internal Carotid Artery Stenosis

1. Symptomatic Patients (Recent TIA or Non‑Disabling Stroke)

1.1 Urgent Evaluation & Timing

• Patients with a recent TIA or non‑disabling stroke and ipsilateral 50‑99 % carotid stenosis must be evaluated promptly by a stroke specialist. [1][2]3
• Carotid endarterectomy (CEA) should be performed within 14 days of symptom onset, ideally within the first few days if the patient is clinically stable. [1][4][5][6]3
• The benefit of CEA declines sharply after 2 weeks; early surgery markedly reduces the risk of recurrent stroke. [2][3]

1.2 Revascularization Indications

• For symptomatic 60‑79 % stenosis, CEA is strongly recommended when the operating centre can achieve peri‑operative stroke + death ≤ 6 %, the patient’s life expectancy exceeds 5 years, and no contraindications exist. [1][4][5][6][2][3]
• Although the absolute benefit is greater for ≥ 70 % stenosis, patients with 50‑69 % symptomatic stenosis still derive net benefit; however, women with 50‑69 % stenosis showed no clear advantage in the NASCET trial. [2][3]

1.3 Procedure Selection

• CEA is the preferred revascularization method, especially in patients > 70 years, because carotid artery stenting (CAS) carries higher periprocedural stroke/death rates in this age group. [1][4][7][8]3
• CAS may be considered only when the patient is unsuitable for surgery due to technical, anatomic, or medical reasons (e.g., high cervical lesion, prior neck radiation, contralateral vocal‑cord paralysis). [1][4][5][6]
• When CAS is performed, the interventionalist must demonstrate peri‑operative stroke/death ≤ 5‑6 %. [1][4]7

1.4 Medical Management (Mandatory)

• Dual antiplatelet therapy (aspirin 325 mg + clopidogrel 75 mg) for at least 21 days is recommended for symptomatic patients not undergoing immediate revascularization; thereafter, transition to single‑agent antiplatelet therapy long‑term. [5][6]
• Aggressive risk‑factor control should start immediately, including:
  
  • High‑intensity statin aiming for LDL‑C < 1.8 mmol/L (≈ 70 mg/dL). [2][3]
  • Blood‑pressure optimization with antihypertensives. [1][4][7][3]
  • Diabetes management when present. [1][4]7
  • Smoking cessation. 3
  • Lifestyle measures (diet, exercise). [1][4]3

2. Asymptomatic Patients (60‑79 % Stenosis)

2.1 First‑Line Medical Therapy

• Aggressive medical therapy is the cornerstone, consisting of:
  
  • Single antiplatelet agent (aspirin or clopidogrel). [1][4]7
  • High‑intensity statin therapy. [1][4][7][3]
  • Blood‑pressure control. [1][4]7
  • Comprehensive risk‑factor modification as outlined for symptomatic patients. [1][4][7][3]

2.2 Selective Revascularization

• CEA may be offered to asymptomatic patients only when all of the following are satisfied:
  
  • Life expectancy > 5 years. [1][4][9][7]10
  • Surgeon/centre peri‑operative morbidity/mortality < 3 %. [1][4][9][7]10
  • Presence of high‑risk plaque features (e.g., ulceration, intraplaque hemorrhage). 11
  • Informed patient preference after discussion of risks/benefits. 12
• Routine revascularization is not advised for asymptomatic patients with life expectancy < 5 years or without high‑risk plaque characteristics. [5][6]

2.3 Imaging Requirements

• Computed tomography angiography (CTA) is the preferred modality for quantifying stenosis severity and guiding surgical decisions. [1][4][9][8]
• Duplex ultrasound (DUS) is acceptable for initial screening but has limited accuracy for precise stenosis measurement. [5][6]11
• Stenosis should be measured using the NASCET method. [5][6]

3. Post‑Revascularization Surveillance

• Duplex ultrasound surveillance within the first month after CEA or CAS is recommended. [5][6]
• After CAS, continue dual antiplatelet therapy for at least 1 month; after CEA, single antiplatelet therapy long‑term. [5][6]
• Long‑term single antiplatelet therapy (aspirin or clopidogrel) is advised for all patients after revascularization. [5][6]
• Annual clinical follow‑up should assess neurological status, cardiovascular risk factors, and adherence to therapy. [5][6]
• Aggressive medical management must be maintained irrespective of whether revascularization was performed. [1][4][7][3]

4. Critical Pitfalls to Avoid

• Do not postpone CEA beyond 14 days in symptomatic patients, as the benefit diminishes substantially. [1][4][2][6]3
• Do not perform CAS in patients > 70 years unless they are true non‑surgical candidates; outcomes are inferior to CEA. [1][4][7][8]3
• Do not proceed with revascularization if the surgeon/centre cannot demonstrate the required low complication thresholds (< 6 % for symptomatic, < 3 % for asymptomatic). [1][4][7][5]6
• Do not neglect medical management; it is mandatory for all patients. [1][4][7][3]
• Do not routinely revascularize asymptomatic patients without careful selection based on life expectancy and surgical risk. [5][6]12

Perioperative Risks and Procedure Selection for Symptomatic Carotid Stenosis

Perioperative Stroke/Death Rates

• In symptomatic patients undergoing carotid endarterectomy (CEA), peri‑operative stroke or death occurs in 2 %–10 % of cases overall, with high‑quality centers achieving rates of 3.9 %–6.3 %. 13

Preference of Carotid Endarterectomy over Stenting

• Carotid endarterectomy is strongly preferred to carotid artery stenting (CAS) for symptomatic stenosis because CAS is associated with higher peri‑operative stroke/death rates (9.5 %–11.1 % for CAS vs. 6.3 %–8.8 % for CEA). 13

Age Considerations for Stenting

• Patients older than 70 years should not receive carotid artery stenting unless they are true non‑surgical candidates, as outcomes in this age group are inferior to those of CEA. 13

Management of Asymptomatic Carotid Artery Stenosis

Foundational Medical Therapy

• Intensive medical therapy is the primary treatment for all patients with asymptomatic carotid stenosis ≥ 60 %; selective revascularization is reserved for those with ≥ 70 % stenosis, a life expectancy > 5 years, high‑risk plaque features, and treatment at centers achieving a peri‑operative stroke/death rate < 3 % (European Society of Cardiology) 14.
• All patients should receive single antiplatelet therapy (aspirin 75‑325 mg daily or clopidogrel 75 mg daily) (American College of Cardiology) 15.
• High‑intensity statin therapy aiming for LDL‑C < 1.8 mmol/L (≈70 mg/dL) is recommended (European Society of Cardiology) 16.
• Blood pressure should be optimized with antihypertensive agents (American College of Cardiology) 17.
• Diabetes mellitus, when present, must be managed according to contemporary glycaemic targets (European Society of Cardiology) 14.
• Smoking cessation counseling and support are mandatory (European Society of Cardiology) 16.
• Lifestyle modification—including a heart‑healthy diet and regular aerobic exercise—is advised (American College of Cardiology) 15.

Revascularization Decision Criteria

• Stenosis severity – < 60 %: medical therapy alone; 60‑69 %: medical therapy alone in most cases; ≥ 70 %: further evaluation required (European Society of Cardiology) 14.
• Life expectancy – Patients with < 5 years expected survival should receive medical therapy only; those with ≥ 5 years may be considered for revascularization (European Society of Cardiology) 18.
• Center performance – Revascularization is permissible only at institutions that can demonstrate a peri‑operative stroke/death rate < 3 % (European Society of Cardiology) 18.
• High‑risk plaque features that justify revascularization – ulcerated plaque, intraplaque haemorrhage, rapidly progressive stenosis, contralateral carotid occlusion, or silent cerebral infarction on imaging (European Society of Cardiology; Cardiovascular Research) 19.

Selection of Revascularization Modality

• Patients < 70 years – Carotid endarterectomy (CEA) is preferred for average‑risk patients; carotid artery stenting (CAS) may be considered as an alternative in average‑risk patients or when surgical risk is high (e.g., prior neck surgery, radiation, high cervical lesion, contralateral vocal‑cord paralysis) (European Society of Cardiology; American Heart Association) 18.
• Patients ≥ 70‑75 years – CEA is strongly preferred because CAS is associated with higher peri‑operative stroke rates in this age group; CAS should be used only in true non‑surgical candidates (European Society of Cardiology; American Heart Association) 18.

Post‑Procedural Management

• After CEA – continue single antiplatelet therapy indefinitely, maintain peri‑operative blood pressure control, and perform a neurological examination within 24 hours (American College of Cardiology) 15.
• After CAS – administer dual antiplatelet therapy (aspirin 81‑325 mg + clopidogrel 75 mg) for at least 30 days, initiated before the procedure; use an embolic protection device; ensure peri‑operative blood pressure control and a neurological exam within 24 hours (American College of Cardiology) 15.

Surveillance and Ongoing Care

• Duplex ultrasound surveillance – obtain imaging at 1 month, 6 months, then annually; intervals may be extended once disease stability is confirmed (American College of Cardiology) 17.
• Intensive medical therapy should be continued indefinitely, regardless of revascularization status (European Society of Cardiology) 16.

Clinical Pitfalls to Avoid

• Do not revascularize patients with a life expectancy < 5 years (European Society of Cardiology) 18.
• Do not proceed if the treating centre cannot document a peri‑operative complication rate < 3 % (European Society of Cardiology) 18.
• Avoid CAS in patients > 70‑75 years unless they are true non‑surgical candidates (European Society of Cardiology) 18.
• Do not revascularize asymptomatic stenosis < 70 % (Journal of Neurointerventional Surgery) 20.
• Do not discontinue intensive medical therapy after successful revascularization (European Society of Cardiology) 14.
• Do not use long‑term dual antiplatelet therapy in asymptomatic patients who have not undergone revascularization (American College of Cardiology) 15.

Special Considerations: Carotid Stenosis in Patients Undergoing Cardiac Surgery

• In patients with ≥ 80 % carotid stenosis scheduled for coronary artery bypass grafting, the untreated peri‑operative stroke risk rises to ≈ 9 % (Cardiovascular Research) 19.
• Staged or synchronous carotid revascularization should be contemplated for symptomatic patients or those with bilateral high‑grade stenosis (Cardiovascular Research) 19.
• Routine prophylactic revascularization is not recommended for unilateral asymptomatic stenosis before CABG (Cardiovascular Research) 19.
• Decisions require a multidisciplinary Heart Team and Neurovascular Team evaluation (Cardiovascular Research) 19.